ArticleBMC pediatrics2025
Value of elevated 1-hour post-load plasma glucose level in identifying risk of MAFLD in non-diabetic obese children and adolescents.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- One-Hour Post-Load Glucose Is Associated with Multisystem Complications in People Living with Obesity.Biomolecules · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveTo evaluate the potential value of 1-h post-load plasma glucose level in patients who are prone to suffer from metabolic associated fatty liver disease (MAFLD) in a group of non-diabetic obese children and adolescents.
methodsCardio-metabolic risk factors, oral glucose tolerance test outcomes, and Liver ultrasonic examination results were analyzed in 406 non-diabetic obese children and adolescents. Patients were divided into 4 groups: normal glucose tolerance with 1-h plasma glucose (NGT with 1-h PG) < 8.6 mmol/L, NGT with 1-h PG ≥ 8.6 mmol/L, impaired fasting glucose (IFG), and impaired glucose tolerance (IGT).
resultsIn this study, 406 non-diabetic children and adolescents with obesity (249 males, 157 females, mean age: 11.71 ± 2.22 years) were included. Among them, 286 (70.4%) had NGT, 30 (7.4%) had IFG, and 90 (22.2%) had IGT. As compared with NGT with 1-h PG < 8.6 mmol/L, NGT with 1-h PG ≥ 8.6 mmol/L and IGT groups demonstrated significantly higher body fat percentage, obesity family history, triglycerides, gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST). After adjusting for age, sex, and BMI z-score, the 1-h PG level demonstrated significant positive correlations with ALT (Spearman's ρ = 0.12, P = 0.018), AST (ρ = 0.15, P = 0.003), and GGT (ρ = 0.21, P < 0.001). In the multivariable-adjusted logistic regression model controlling for age, sex, BMI z-score, body fat percentage, homeostatic model assessment of insulin resistance and glycosylated hemoglobin, individuals with NGT and 1-h PG ≥ 8.6 mmol/L exhibited 1.882-fold higher odds of MAFLD (95% CI 1.045-3.388), while the IGT group showed significantly elevated odds (OR = 1.980, 95% CI 1.056-3.709). No statistically significant association was observed in the IFG group.
conclusionThese data suggest that NGT with 1-h PG ≥ 8.6 mmol/L in non-diabetic obese pediatric patients can facilitate identifying individuals at higher risk of MAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.